Investor Overview

Webcast ImageWebcast
Verastem Research and Development Day 2014 (Replay)
07/10/14 at 12:30 p.m. ET
Verastem Research and Development Day 2014
Thursday, July 10, 2014 12:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.64
Change (%) Stock is Up 0.16 (1.89%)
Volume325,880
Data as of 07/11/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
07/10/14Verastem Presents Results and Updated Development Plans at Annual Research and Development Day
-Lead cancer stem cell inhibitor VS-6063 continues to show promise in the clinic- -An additional partial response reported since ASCO in the combination trial of VS-6063 and paclitaxel in ovarian cancer- -64% stable disease or better as best clinical response to date, including five objective responses, in the ongoing combination trial of VS-6063 and paclitaxel in ovarian cancer- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 10, 2014... 
Printer Friendly Version
07/08/14Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day on July 10, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that it will ring the Closing Bell at the NASDAQ MarketSite in Times Square, New York City, on Thursday, July 10, 2014, at 4:00 p.m. ET. The Closing Bell ceremony will take place immediately following the conclusion of the Company’s annual Research and D... 
Printer Friendly Version
06/24/14Verastem’s Published Scientific Data on Targeting Mesothelioma Cancer Stem Cells Receives Coverage in AACR’s Cancer Discovery
- The Registration-Directed COMMAND Study of VS-6063 for Patients with Malignant Pleural Mesothelioma to be Highlighted at the Company’s Upcoming R&D Day on July 10 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced publication of an article titled “FAK Inhibitor Kills Mesothelioma Cells” in ... 
Printer Friendly Version
06/18/14Verastem Announces Annual Research and Development Day and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company will host its annual Research and Development Day on Thursday, July 10, 2014 from 12:30 – 4:00pm ET at The Hudson Theatre at the Millennium Broadway Hotel in New York City. The Company will provide updates regarding its research a... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.